Two peptides developed behind the Iron Curtain now occupy a prominent position in contemporary nootropic research. Selank, a synthetic heptapeptide with GABAergic anxiolytic activity, and Semax, an ACTH-derived fragment that upregulates brain-derived neurotrophic factor, were both created at the Institute of Molecular Genetics in Moscow — yet their mechanisms are distinct enough that researchers frequently study them in tandem. This deep dive covers the origins, pharmacology, and preclinical research profiles of both compounds, and explains why they have attracted sustained scientific interest since the 1980s.

Origins: Soviet Neuropharmacology and the Institute of Molecular Genetics

Modern peptide nootropic research owes a substantial debt to Soviet neuroscience. From the late 1970s onward, researchers at the Institute of Molecular Genetics (IMG) in Moscow pursued a systematic programme of neuropeptide synthesis, seeking pharmacological tools that could modulate cognition and stress without the side-effect profile of classical benzodiazepines or stimulants. The institutional context mattered: the Soviet military and space programme had a direct interest in agents that could sustain cognitive performance under high-stress conditions, and the IMG was given significant resources to pursue that goal.

Semax emerged first, developed during the 1980s as a synthetic analogue of the adrenocorticotropic hormone (ACTH) fragment spanning positions 4 through 7, extended with a Pro-Gly-Pro C-terminal tripeptide to improve metabolic stability. The parent ACTH(4-7) sequence — Met-Glu-His-Phe — had been identified as possessing cognitive-modulating activity in earlier animal research, but its rapid enzymatic degradation in biological fluids made it impractical as a research tool. The Pro-Gly-Pro extension substantially prolonged the effective half-life without altering the core pharmacophore.

Selank followed in the 1990s, synthesised as a heptapeptide analogue of tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen and known for its immunomodulatory properties. The research team at the IMG extended tuftsin with a Trp-Pro-Arg C-terminal addition, yielding the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The structural modification preserved tuftsin’s immunomodulatory character while conferring a new and clinically interesting anxiolytic activity profile.

Both compounds were approved for clinical use in Russia — Semax as a nasal spray for stroke management and cognitive decline, Selank as a prescription anxiolytic — giving them an unusually detailed human-use record by the standards of nootropic peptides. Outside Russia, however, they remain strictly in the preclinical research domain.

Selank Benefits: GABAergic Mechanism and Anxiolytic Research Profile

Selank’s primary research interest lies in its anxiolytic activity, which operates through a mechanism distinct from classical benzodiazepines. In vitro and in vivo preclinical data indicate that Selank modulates GABA-A receptor function — enhancing the affinity of GABA for its receptor complex — rather than binding directly at the benzodiazepine allosteric site. This distinction is pharmacologically significant: benzodiazepines produce tolerance partly because chronic allosteric site occupancy leads to receptor internalisation and subunit remodelling. Selank’s indirect modulation of GABA-A activity, if borne out in further mechanistic research, may represent a qualitatively different interaction with the GABAergic system.

Preclinical studies in rodent models have reported several findings relevant to stress and anxiety research:

• Stress biomarker modulation: In rat models of chronic unpredictable stress, Selank administration was associated with attenuated elevations in corticosterone, a primary biomarker of HPA axis activation. Researchers interpreting these data suggest Selank may blunt stress-axis reactivity without suppressing baseline corticosterone to pharmacologically problematic levels.
• Elevated plus-maze performance: Rodents administered Selank displayed increased open-arm exploration in the elevated plus-maze — a standard assay for anxiolytic activity — at doses that did not produce sedation or impair motor coordination in rotarod testing. This distinguishes its preclinical profile from benzodiazepines, which typically produce sedation at anxiolytic doses.
• Serotonin and dopamine system interactions: Beyond the GABAergic pathway, Selank has been reported to modulate serotonergic tone, specifically influencing 5-HT transporter expression in the hippocampus and prefrontal cortex in rodent studies. Dopaminergic effects — including modest increases in dopamine turnover in the striatum — have also been reported, suggesting the peptide’s activity is not confined to a single monoamine system.
• Immunomodulatory activity: Consistent with its tuftsin lineage, Selank retains some immunological activity. Preclinical research has described modulation of interleukin-6 expression under inflammatory challenge, though the relevance of this finding to the peptide’s anxiolytic profile is not yet established.

Researchers studying stress-resilience mechanisms consider Selank a useful experimental tool precisely because its multi-target profile — GABAergic, serotonergic, and immunological — allows investigation of the crosstalk between these systems in anxiety-like behaviour.

For researchers sourcing material, Biohacker’s Selank capsules are produced at 99%+ HPLC purity with batch-level certificates of analysis available at the COA portal.

Semax as a Nootropic: BDNF Upregulation and Neuroprotective Research

Where Selank is primarily studied for its anxiolytic and stress-modulating properties, Semax occupies a different research niche: cognitive activation and neuroprotection. Its most replicated and mechanistically interesting finding is upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex of rodent models.

BDNF is a member of the neurotrophin family that plays a central role in synaptic plasticity, long-term potentiation (LTP), and the survival of existing neurons. BDNF signalling through the TrkB receptor is widely regarded as a key mediator of learning and memory consolidation; its downregulation is implicated in depression, cognitive ageing, and neurodegeneration. Compounds that reliably upregulate BDNF expression are therefore of substantial research interest.

In rodent studies, Semax administration has been associated with:

• Hippocampal BDNF elevation: Multiple independent groups have reported 1.5- to 3-fold increases in hippocampal BDNF mRNA and protein levels following Semax administration in rats, with effects observed within hours of a single dose and persisting for up to 24 hours in some protocols.
• Enhanced LTP in hippocampal slice preparations: Consistent with its BDNF-upregulating activity, Semax has been shown to facilitate LTP induction in hippocampal CA1 slices — a well-validated electrophysiological correlate of synaptic memory mechanisms.
• Neuroprotection in ischaemia models: Semax has been extensively studied in rodent stroke models, where it has demonstrated reductions in infarct volume, attenuation of peri-infarct excitotoxicity, and improved behavioural recovery scores. These findings underpinned its clinical registration in Russia as a nasal spray adjunct in ischaemic stroke management — a regulatory approval that provides an important E-E-A-T anchor for its safety characterisation in humans, though human data remain limited by Western regulatory standards.
• NGF pathway modulation: In addition to BDNF, Semax has been reported to modulate nerve growth factor (NGF) expression in basal forebrain cholinergic nuclei — regions with direct relevance to attentional processing and memory encoding.
• Dopaminergic activity: Semax interacts with the dopaminergic system in a manner consistent with mild psychostimulant-like activity in some assay formats, including increased locomotor exploration and enhanced performance on novel object recognition tasks. These effects are considerably milder than classical stimulants and are not accompanied by sensitisation in repeat-dosing protocols studied to date.

Biohacker’s Semax capsules are formulated with enteric protection to address the oral bioavailability challenges inherent in peptide compounds (see below). Each batch is independently third-party tested; COAs are published at biohacker.dev-up.click/coas/.

Head-to-Head: Selank vs Semax Research Profiles

The two peptides are frequently discussed together because their research profiles are complementary rather than redundant. The table below summarises the key distinguishing characteristics.

The logic behind studying them in combination is straightforward: anxiety and cognitive impairment frequently co-occur, and the mechanisms underlying them — HPA dysregulation, reduced GABAergic tone, diminished BDNF signalling — interact bidirectionally. A research protocol that modulates both axes simultaneously may yield more ecologically valid data on stress-cognition interactions than either compound alone.